Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Income from Continuing Operations: 2019-2023

Historic Income from Continuing Operations for ADC Therapeutics (ADCT) over the last 5 years, with Sep 2023 value amounting to -$45.3 million.

  • ADC Therapeutics' Income from Continuing Operations rose 12.93% to -$45.3 million in Q3 2023 from the same period last year, while for Sep 2023 it was -$153.5 million, marking a year-over-year decrease of 11.71%. This contributed to the annual value of -$153,522 for FY2022, which is 43.76% up from last year.
  • ADC Therapeutics' Income from Continuing Operations amounted to -$45.3 million in Q3 2023, which was up 6.01% from -$48.2 million recorded in Q2 2023.
  • Over the past 5 years, ADC Therapeutics' Income from Continuing Operations peaked at -$16,223 during Q4 2022, and registered a low of -$126.3 million during Q2 2020.
  • In the last 3 years, ADC Therapeutics' Income from Continuing Operations had a median value of -$51.3 million in 2021 and averaged -$44.1 million.
  • Per our database at Business Quant, ADC Therapeutics' Income from Continuing Operations crashed by 480,314.45% in 2020 and then spiked by 79.29% in 2022.
  • Over the past 5 years, ADC Therapeutics' Income from Continuing Operations (Quarterly) stood at -$35,055 in 2019, then slumped by 65,908.76% to -$20.3 million in 2020, then slumped by 250.44% to -$78,323 in 2021, then surged by 79.29% to -$16,223 in 2022, then climbed by 12.93% to -$45.3 million in 2023.
  • Its last three reported values are -$45.3 million in Q3 2023, -$48.2 million for Q2 2023, and -$60.0 million during Q1 2023.